The Transcription Factor EGR1 Controls Both the Proliferation and Localization of Hematopoietic Stem Cells  by Min, Irene M. et al.
Cell Stem Cell
ArticleThe Transcription Factor EGR1 Controls
Both the Proliferation and Localization
of Hematopoietic Stem Cells
Irene M. Min,1,4,5 Giorgio Pietramaggiori,1,2,4,5 Francis S. Kim,1,4,5 Emmanuelle Passegue´,6 Kristen E. Stevenson,3
and Amy J. Wagers1,4,5,*
1Section on Developmental and Stem Cell Biology, Joslin Diabetes Center
2Division of Plastic Surgery, Brigham and Women’s Hospital, Harvard Medical School
3Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute
Boston, MA 02115, USA
4Department of Stem Cell and Regenerative Biology, Harvard University
5Harvard Stem Cell Institute
Cambridge, MA 02138, USA
6Institute for Regeneration Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
*Correspondence: amy.wagers@joslin.harvard.edu
DOI 10.1016/j.stem.2008.01.015SUMMARY
EGR1 is a member of the immediate early response
transcription factor family and functions in cell
growth, development, and stress responses in many
tissues. Here we report an additional role for EGR1 in
regulating homeostasis of hematopoietic stem cells
(HSCs). HSCs normally express Egr1 at high levels,
but dramatically downregulate its expression when
induced to divide and migrate. Consistent with this
finding, mice lacking Egr1 exhibit significant in-
creases in steady-state levels of dividing HSCs in
the bone marrow (BM), and a striking spontaneous
mobilization of HSCs into the peripheral blood. These
data identify EGR1 as a transcriptional regulator of
stem cell migration that normally functions to pro-
mote HSC quiescence and retention in the niche.
The ability of this single factor to regulate both prolif-
eration and mobilization of HSCs suggests that EGR1
commands a genetic program that coordinates stem
cell division and migration to maintain appropriate
HSC number and function.
INTRODUCTION
Hematopoiesis in adult animals is sustained by a small popula-
tion of clonogenic, multipotent hematopoietic stem cells
(HSCs), which maintain throughout life the capacity to self-renew
and to differentiate to give rise to progeny cells that ultimately
generate all cells of the hematopoietic system. In normal mice
and humans, HSCs are found predominantly in the bone marrow
(BM), where signals from the surrounding microenvironment, or
‘‘niche,’’ hold them in a state of relative dormancy (Arai et al.,
2005). Yet despite their usual quiescence, HSCs are capable
of dramatic expansion in response to hematopoietic stress,
which can be signaled by cytotoxic injury, hematodepletion, in-
fection, or stem cell-activating cytokines.380 Cell Stem Cell 2, 380–391, April 2008 ª2008 Elsevier Inc.Many studies in gene-targeted mice indicate that regulation of
stem cell numbers in the BM can be accomplished through direct
modulation of HSC proliferation (Cheng et al., 2000; Hock et al.,
2004; Kozar et al., 2004; Malumbres et al., 2004; Sandberg et al.,
2005) or resistance to apoptosis (Domen et al., 2000). Yet recent
observations hint that physiological HSC frequencies may also
be regulated through controlled migration of HSCs into and out
of the BM compartment. While the majority of HSCs are normally
in BM, HSCs are also constitutively present at low levels in the
circulation (Fleming et al., 1993; Wright et al., 2001b). These
rare, blood-borne HSCs can be detected functionally both by
direct transplantation and by parabiosis experiments, which
further indicate that circulating HSCs rapidly re-engraft BM at
distinct locations and functionally contribute to ongoing BM
hematopoiesis (Wright et al., 2001b) as well as peripheral
immune responses (Massberg et al., 2007). Thus, constitutive,
low-level turnover of HSC niches, with seeding from blood-borne
HSCs, occurs constantly in normal, unconditioned animals
(Bhattacharya et al., 2006), and may contribute directly to the
maintenance of physiologically appropriate numbers of HSCs
and their differentiating daughter cells.
To better understand the molecular and cell biological pro-
cesses governing HSC number and localization in vivo, we
searched for genes that are regulated during pharmacologically
induced HSC expansion and migration. These studies revealed
significant alteration in expression by proliferating and migrating
HSCs of the transcription factor Early growth response 1 (Egr1,
also known as NGFI-A, krox-24, ZIF268, and TIS8 [Christy
et al., 1988; Lemaire et al., 1988; Milbrandt, 1987; Sukhatme
et al., 1988]). Egr1 is an immediate early response gene and
founding member of a family of zinc-finger transcription factors
that include Egr2, Egr3, and Egr4 (Gashler and Sukhatme,
1995). Once bound to DNA, EGR1 can act as either an activator
or a repressor of transcription, through mechanisms that depend
on interactions with or regulation of distinct cofactors (reviewed
in Thiel and Cibelli, 2002).
In the hematopoietic system, Egr1 is expressed in both lym-
phoid and myeloid cells (Bettini et al., 2002; Laslo et al., 2006;
Lee et al., 1995b, 1996b), and has been implicated in the
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sors (Bettini et al., 2002; Dinkel et al., 1998; Schnell and Kersh,
2005; Schnell et al., 2006). Overexpression of Egr1 in mouse
BM cells appears to enhance macrophage development at the
expense of granulocyte and erythroid differentiation (Krishnaraju
et al., 2001). Interestingly, Egr1-overexpressing BM cells fail to
protect lethally irradiated recipients from death due to hemato-
poietic failure, and fail to reconstitute hematopoietic colony-
forming cells in recipient BM at 10 days posttransplant (Krishnar-
aju et al., 2001). These data suggest that EGR1 is capable of
modulating the function of very primitive hematopoietic precur-
sor cells, and prompted us to further investigate its function in
hematopoietic cell development using Egr1 ‘‘knockout’’ (Egr1/)
mice (Lee et al., 1995a).
We report here that in wild-type BM, Egr1 expression is
enriched within the most primitive subset of long-term (LT)
reconstituting HSCs; however, Egr1 is dramatically reduced
when HSCs are stimulated to proliferate and migrate in response
to pharmacologic mobilization. Absence of Egr1 in Egr1/ mice
leads to a significant increase in HSC proliferation in the BM, but
only modest increases in the overall size of the BM HSC pool.
Egr1/ mice also exhibit a striking increase in the number of
functional HSCs in the peripheral blood (PB), implicating EGR1
target genes in promoting HSC retention in the BM niche. Taken
together, these data identify EGR1 as a transcriptional regulator
of HSC localization in vivo, and further indicate that this factor
normally plays a crucial role in maintaining appropriate HSC qui-
escence in the BM. The ability of this single gene to modulate
both the self-renewal potential and anatomical localization of
HSCs suggests that a molecularly coordinated and biologically
significant relationship between HSC division and migration
may directly regulate HSC number and function.
RESULTS
Egr1 Is Highly Expressed by LT-HSCs
and Downregulated during Mobilization
Immediate early transcription factors are a family of genes
initially identified for their rapid, transcription-independent acti-
vation upon serum exposure and cell-cycle re-entry of serum-
starved cells. These factors have been implicated in responses
to a wide variety of cellular stimuli and exhibit cell type- and con-
text-dependent roles in cell growth, development, death, and
differentiation (reviewed in Herschman, 1991). Previous studies
suggest a variety of functions for members of this gene family
within the hematopoietic system, including regulation of cell-
fate decisions of differentiating blood precursors (Krishnaraju
et al., 2001), proliferation/survival of mature and immature hema-
topoietic cells (Bettini et al., 2002), and leukemic transformation
of HSCs (Passegue et al., 2004).
To evaluate the potential role of immediate early response
transcription factors in HSC proliferation and migration, we de-
termined the relative expression of four members of this gene
family (JunB, c-jun, c-fos, and Egr1) in c-kit+Thy1.1loLineage
markerSca-1+ (KTLS) HSCs (Morrison and Weissman, 1994),
purified by fluorescence-activated cell sorting (FACS) from un-
treated mice or from mice treated with a combination of cyclo-
phosphamide (Cy) and granulocyte colony-stimulating factor
(G-CSF). Treatment of mice with Cy followed by sequential dailydoses of G-CSF (G) induces rapid and reproducible HSC mobi-
lization, which begins with a massive (10- to 12-fold) proliferative
expansion of HSCs in the BM that peaks at day +2 (D+2) of the
treatment regimen (see Figure S1 available online), and proceeds
with the subsequent migration of recently divided HSCs from the
BM into the peripheral blood (PB) and spleen (SP) of mobilized
animals (Morrison et al., 1997; Wright et al., 2001a). Significantly,
after D+2, HSC frequency in the BM declines, and the rate of BM
HSC proliferation returns to normal by day +4 (D+4) (Morrison
et al., 1997; Passegue et al., 2005). Thus, D+2 Cy/G-treated
HSCs represent a rapidly expanding, premigratory HSC popula-
tion, and genes differentially expressed by these cells, as com-
pared to untreated, quiescent HSCs, are likely to be involved in
HSC self-renewal and/or release from the BM environment.
Quantitative RT-PCR (qRT-PCR) analysis of KTLS HSCs re-
vealed substantially reduced expression in D+2 Cy/G-mobilized
HSCs of all four immediate early response transcription factors
we examined; the most strongly downregulated gene was Egr1
(reduced to 20% the levels in HSCs from untreated mice,
Figure 1A). Normal levels of expression of Egr1, as well as other
immediate early transcription factors, were recovered in D+4 BM
HSCs (Figure 1A), which previously have been shown to exhibit
a return to normal cell number (Morrison et al., 1997) and normal
cell-cycle profile (Passegue et al., 2005) (see Figure S1).
Notably, in unmanipulated mice, Egr1 expression was dramat-
ically elevated specifically among multipotent BM cells (i.e.,
those contained within the c-kit+LinSca-1+ [KLS] fraction and
capable of differentiating to both lymphoid and myeloid cells).
Egr1 expression was highest among the most primitive, most
quiescent, LT-HSCs, defined by the cell surface phenotype
KLSFlk2 (KLSF) (Figure 1B) (Adolfsson et al., 2001; Christensen
and Weissman, 2001). Egr1 expression diminished as HSCs dif-
ferentiated to KLSFlk2+ multipotent progenitors (MPP), a process
that is accompanied by loss of self-renewal potential and an in-
creased rate of proliferation (Adolfsson et al., 2001; Christensen
and Weissman, 2001; Forsberg et al., 2006) (Figure 1B). This
selective high-level expression of Egr1 by quiescent HSCs, to-
gether with its substantial repression during Cy/G-induced HSC
expansion and initiation of migration, suggested that EGR1
may normally act to control HSC homeostasis in the BM by limit-
ing HSC cell-cycle entry and/or by restricting HSC migration.
Egr1/ HSCs Show Enhanced Proliferation
To evaluate the role of EGR1 in LT-HSC maintenance and func-
tion, we analyzed Egr1/ mice (Egr1tm1Jmi/Egr1tm1Jmi) lacking
this transcription factor (Lee et al., 1995a, 1996a). Previous stud-
ies involving Egr1/ mice have indicated a complete absence of
EGR1 protein in these animals, but suggested few physiologic
abnormalities resulting from EGR1 deficiency aside from female-
specific infertility due to impaired production of luteinizing hor-
mone b (Lee et al., 1995a, 1996a, 1996b) and modest effects
on thymic progenitor cells (Bettini et al., 2002; Schnell and Kersh,
2005; Schnell et al., 2006). Likewise, our analyses showed no
alterations in the steady-state levels of mature lymphoid or my-
eloid cells in the PB of Egr1/ mice (Figure S2).
To determine the impact of EGR1 deficiency on the rate of
HSC proliferation, we analyzed the cell-cycle profile of Egr1/
BM HSCs. HSCs were identified for these studies as either
KLS CD34 (KLS34) (Figure 2A, left, and Figure 2B) or KLSCell Stem Cell 2, 380–391, April 2008 ª2008 Elsevier Inc. 381
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LT-HSCs and Downregulated by Cy/G
Mobilization
(A) Expression of immediate early response genes
was determined by qRT-PCR for double-sorted
KTLS HSCs isolated from untreated (D-1 BM), or
Cy/G-treated BM (D+2 BM or D+4 BM) or spleen
(D+4 SP), at the indicated time points (day 1,
day +2, or day +4) of the Cy/G-mobilization
regimen. In all experiments, mice receive Cy on
day 1, and subsequent daily doses of G. Mice
were sacrificed for analysis on the indicated days
in lieu of treatment. Values have been normalized
for b-actin expression levels, and for each gene,
relative expression at each time point is expressed
as fold induction compared to the level (set to 1) detected in D-1 HSCs. Results (mean + SD) are obtained from three independently sorted sets of populations
(***p% 0.001).
(B) Egr1 levels relative to b-actinmRNA were determined by qRT-PCR for lineage-depleted bone marrow (Lin BM) or the indicated populations of double-sorted
BM cells. Results were obtained from three independent experiments and are presented as fold difference in relative expression (mean + SD) compared to the
average level (set to 1) detected in Lin BM (***p% 0.001).Flk2 (KLSF) (Figure 2A, right) (Adolfsson et al., 2001; Christen-
sen and Weissman, 2001; Ito et al., 2000). Hoechst 33342 stain-
ing for DNA content of sorted HSCs revealed an2-fold increase
in the percent of Egr1/ HSCs in S/G2-M phases of the cell cy-
cle, when compared with wild-type controls (Figure 2A) (***p%
0.001 by Wilcoxon test; n = 7–9 per group). This increased rate
of proliferation of Egr1/ LT-HSCs in BM was confirmed by
in vivo BrdU incorporation assays, which similarly showed 2-
fold greater incorporation of BrdU in Egr1/ as compared to
Egr1+/+ KLS34 HSCs (Figure 2B) (***p % 0.01 by Wilcoxon
test; n = 5 per group). In addition, as expected based on their
increased proliferative activity, Egr1/ HSCs also showed
reduced resistance to treatment with the myeloablative agent
5-fluorouracil (5-FU), which preferentially kills dividing cells.
One day after administration of 5-FU, the average frequency of
BM HSCs in Egr1/ animals was only 76% ± 7% (mean ±
SEM) the level in wild-type littermate controls (p = 0.004; n =
three independent experiments).
These data demonstrate by multiple, independent assays that
Egr1/HSCs exhibit enhanced proliferative activity. Yet, despite
the consistent increase in steady-state HSC proliferation in
Egr1/ mice, these animals showed only subtle changes in the
overall frequency and number of HSCs in the BM. By flow cytom-
etry, the average frequency of LT-HSCs defined by the KLS34
marker profile was increased by only 80% in Egr1/ mice as
compared toEgr1+/+ littermates (Figure 2C, left, *p% 0.05 by Wil-
coxon test; n = 5–8 per group), which translated to an 2.4-fold
increase in total numbers of KLS34 HSCs in the BM of Egr1/
mice (Figure 2D, left, *p% 0.05). However, consistent with previ-
ous reports (Schnell et al., 2006), steady-state frequencies and
numbers of the KLSF population were not significantly altered
in Egr1/ BM (Figure 2C, right, p = 0.27; n = 9–12 per group,
and Figure 2D, right, p = 0.3 by Wilcoxon test).
Thus, enhanced proliferative activity among Egr1/ HSCs
does not lead to substantial accumulation of these cells in the
BM. This failure of rapidly proliferating Egr1/ HSCs to accumu-
late in the BM does not appear to reflect decreased HSC sur-
vival, as the frequency of apoptotic BM HSCs was equivalent
in Egr1/ versus Egr1+/+ mice (Figure 2E). These data suggest
that additional regulatory mechanisms must limit HSC accumu-
lation in the BM of Egr1/ mice (see below).382 Cell Stem Cell 2, 380–391, April 2008 ª2008 Elsevier Inc.Enhanced Proliferation of Egr1/ HSCs Is Cell
Autonomous and Associated with Altered Expression
of Bmi-1, cdk4, and p21
To assess the cell-intrinsic versus -extrinsic actions of EGR1 on
HSC cycling, we analyzed the proliferative activity of clonally
sorted Egr1+/+ or Egr1/ HSCs. Single HSCs isolated from the
BM of Egr1+/+ or Egr1/ mice were cultured in serum-free me-
dium supplemented with a minimal cytokine cocktail previously
reported to promote HSC self-renewing divisions for up to
3 days in vitro (Ema et al., 2000; Uchida et al., 2003). Under these
conditions, the rate of colony growth from single Egr1/ HSCs
was significantly faster (*p% 0.05, **p% 0.01) than that of colo-
nies formed from single Egr1+/+ HSCs (Figure 3A, left). This more
rapid accumulation of cells in colonies initiated by single Egr1/
HSCs was not associated with differences in the rate of apopto-
sis of Egr1+/+ versus Egr1/ cells (Figure 3B, right), consistent
with a cell-intrinsic increase in the rate of proliferation of Egr1/
HSCs and their immediate progeny.
To investigate the molecular mechanisms underlying the
enhanced proliferation of Egr1/ LT-HSCs, we next examined
potential changes in the expression of several genes previously
implicated in HSC function. qRT-PCR analysis revealed that
Egr1/ KLSF LT-HSCs exhibited significantly elevated levels
of expression of the polycomb group gene, Bmi1 (Figure 3B,
**p% 0.01), which previously has been implicated in regulating
HSC self-renewal (Iwama et al., 2004; Lessard and Sauvageau,
2003; Park et al., 2003). Mice lacking BMI1 exhibit premature
depletion of hematopoietic stem and progenitor cells (Lessard
and Sauvageau, 2003; Park et al., 2003), while overexpression
of Bmi1 via retrovirus-mediated gene transduction expands
LT-HSCs in vivo (Iwama et al., 2004). In addition, consistent with
their increased fraction of cycling cells, Egr1/ KLSF LT-HSCs
also exhibited significant downregulation of the cell-cycle inhibitor
p21CIP1/WAF1 (p21) and increased expression of cyclin-
dependent kinase 4 (cdk4) (Figure 3B, *p % 0.05). Deletion of
p21 in mice has been reported to cause increased HSC cycling
(Cheng et al., 2000), and lack of cdk4, a catalytic partner of D
type cyclins that can initiate cell-cycle entry (reviewed in Sherr
and Roberts, 1999), contributes to failed hematopoiesis in cdk4/
cdk6 double knockout mice (Malumbres et al., 2004). Consistent
with a role for EGR1 in regulating HSC cell cycle, we also found
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(A) Frequency (%) KLS34 (left) or KLSF (right) BM LT-HSCs in S/G2-M phases (i.e., > 2n DNA content) in Egr1
+/+ or Egr1/ (n = 7–9 per group) mice (***p% 0.001
by Wilcoxon test).
(B) Frequency of BrdU+ KLS34-LT-HSCs in the BM of Egr1+/+ and Egr1/ mice 1 hr after systemic BrdU administration (**p% 0.01; n = 5 per genotype).
(C and D) Frequencies (C) and numbers (D) of KLS34 (left) and KLSF (right) LT-HSCs in Egr1+/+ or Egr1/ BM (2 femurs and 2 tibiae/mouse) were determined by
flow cytometry and total BM cellularity (*p% 0.05 by Wilcoxon test).
(E) Frequency (%) of Annexin V+/PI apoptotic KLS34 (left) or KLSF (right) BM LT-HSCs (n = 9 for each genotype). No significant differences were observed
between Egr1+/+ and Egr1/ mice. Data are presented as boxplots. The middle line in each boxplot indicates the median value, the upper and lower edges
of the boxplot are the 75th and 25th percentiles, and the small horizontal bars denote the 75th percentile + 1.5*interquartile range and 25th percentile  1.5*inter-
quartile range. Filled circles mark the outliers.significant differences in Egr1 mRNA levels in cycling (G1 or S/G2-
M) versus quiescent (G0) HSCs isolated from wild-type (Egr1
+/+)
mice (Figure 3C). qRT-PCR analysis of other previously identified
HSC regulators, including PTEN (Yilmaz et al., 2006; Zhang
et al., 2006), JunB (Passegue et al., 2004), Gfi1 (Hock et al.,
2004), and cyclins D1, D2, and D3 (Kozar et al., 2004), revealed
no differences in their expression by Egr1/ HSCs (Figure 3B
and data not shown). These data demonstrate that Egr1 expres-
sion in HSCs is controlled in a cell-cycle-dependent manner,
and suggest derepression ofBmi1 and cdk4 and reduced expres-
sion of p21 as likely molecular mechanisms underlying the en-
hanced proliferative activity of Egr1/ LT-HSCs.
Loss of Egr1 Does Not Impair Long-Term Hematopoietic
Reconstitution in Primary Recipients, but Causes
Premature HSC Exhaustion in Serial Transplantation
To assay the functional activity of LT-HSCs in Egr1/ mice, we
first employed a noncompetitive transplantation assay in which
‘‘test’’ cells could be distinguished from host cells by expression
of distinct congenic markers (CD45.2 and CD45.1). CD45.2+whole bone marrow (WBM) cells (0.5 3 106) from Egr1+/+ or
Egr1/ mice were transplanted intravenously into lethally irradi-
ated congenic CD45.1+ or F1 (CD45.2+CD45.1+) recipients. At
8 and 14 weeks after transplantation, donor Egr1/ BM cells
exhibited an average engraftment capacity that was equivalent
to Egr1+/+ BM cells, producing equally high numbers of donor-
derived peripheral blood leukocytes (Figures 4A and 4B), BM
cells, and BM KLSF LT-HSCs (Figure 4A).
To quantitatively assess long-term multilineage reconstitution
by LT-HSCs in Egr1/ mice, we next performed competitive BM
transplantation with limiting numbers (25,000 or 100,000) of un-
fractionated BM cells from Egr1+/+ or Egr1/ mice, together
with 200,000 congenic competitor Egr1+/+ BM cells. As shown
in Figures 4C–4F, BM cells from Egr1+/+ and Egr1/ donors
contributed equivalently at early time points to the reconstitution
of mature PB myeloid, B, and T cells. However, at later time
points, animals receiving 25,000 Egr1/ BM cells (correspond-
ing to 15 KLSF HSCs per recipient, see Figure 2) showed
a slightly greater rate of donor-derived, long-term (R19 weeks)
multilineage reconstitution than recipients of 25,000 Egr1+/+ BMCell Stem Cell 2, 380–391, April 2008 ª2008 Elsevier Inc. 383
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EGR1 Regulates Hematopoietic Stem Cell HomeostasisFigure 3. Altered Expression Profile of Cell-Cycle Regulatory Genes inEgr1/Mice andCell-Cycle Regulation ofEgr1 inWild-Type LT-HSCs
(A) Cell-intrinsic regulation of HSC/early progenitor proliferation by Egr1. (Left) Double-sorted single KLSF LT-HSCs were maintained in serum-free medium with
minimal cytokine supplements (Ema et al., 2000; Uchida et al., 2003). HSC/early progenitors from Egr1/ mice proliferated more rapidly than Egr1+/+ cells (*p%
0.05, *p% 0.01; n = 72 for Egr1+/+ and 117 for Egr1/). Data are presented as mean + SD. (Right) The rate of apoptosis (% Annexin V+/PI cells), assayed 3 days
after culture initiation, was similar among Lin Egr1+/+ and Egr1/ HSC/early progenitors, when 200 double-sorted KLSF LT-HSCs were maintained in the same
culture conditions as for single KLSF LT-HSCs (n = 11 for Egr1+/+ and 16 for Egr1/).
(B) Relative expression of indicated mRNA in sorted KSLF LT-HSCs, analyzed by qRT-PCR. n = three to five independent experiments using pooled BM cells from
3–5 mice. Data are presented as mean + SD, and are normalized for b-actin expression as in Figure 1B (*p% 0.05, **p% 0.01).
(C) qRT-PCR analysis of Egr1 expression levels in sorted Egr1+/+ KSLF LT-HSCs at G0, G1, or S/G2-M phases of cell cycle. Cell-cycle stage was distinguished
by staining with Hoechst 33342 and Pyronin Y (PY) as in Passegue et al. (2005). Data are summarized as mean + SD for two independent sort experiments of
3–4 pooled BM cells of Egr1+/+ mice and are normalized for b-actin levels as above (**p% 0.01, ***p% 0.001).cells (Figures 4C–4F). While only 22% (2 of 9) of the recipients
of Egr1+/+ BM cells retained donor lymphoid and myeloid
reconstitution at 19 weeks posttransplant, 70% (7 of 10) of recip-
ients of Egr1/ BM cells exhibited multilineage engraftment at
this time point (p = 0.07 by Fisher’s test), suggesting increased
HSC engraftment in recipients of Egr1/ BM. In fact, increased
contributions of transplanted Egr1/ BM cells to BM HSCs
were confirmed by direct analysis of recipient BM at 30 weeks
posttransplant, and correlated well with chimerism of short-lived
PB myeloid cells (Figure S3). However, in contrast to experi-
ments performed at limiting cell number, transplantation of
higher numbers (100,000/recipient) of donor BM cells yielded
equivalent rates of long-term, multilineage reconstitution and
equal levels of donor-derived peripheral blood leukocytes (Fig-
ures 4C–4F). The fact that Egr1/ BM cells do not engraft
more robustly than wild-type BM at high cell numbers likely re-
flects saturation of the sensitivity of the transplantation assay at
this cell dose.
To assess whether the increased hematopoietic reconstitution
potential of Egr1/ BM cells at limiting cell number reflected the384 Cell Stem Cell 2, 380–391, April 2008 ª2008 Elsevier Inc.slightly higher frequency of HSCs in the BM of Egr1/ mice or an
HSC intrinsic enhancement of engraftment function among
Egr1/ HSCs, we next performed competitive transplantation
assays using purified Egr1/ and Egr1+/+ KLS34 HSCs. Ani-
mals receiving Egr1/ HSCs showed equivalent rates of long-
term, multilineage reconstitution as compared to recipients of
Egr1+/+ HSCs (Figure S4), suggesting that loss of Egr1 in HSCs
does not impact their intrinsic engraftment capacity and that
improved engraftment by Egr1/ WBM at limiting cell number
(Figures 4C–4F) likely reflects the slight increase in HSC fre-
quency within Egr1/ BM (Figures 2C and 2D).
Finally, to test the function of Egr1/ HSCs under conditions
of extreme hematopoietic stress, we performed serial transplan-
tation assays, comparing BM cells harvested from Egr1/ ver-
sus Egr1+/+ mice. We transplanted 106 donor-derived BM cells
from primary recipients of 0.53 106 Egr1+/+ or Egr1/ BM cells
into secondary wild-type (Egr1+/+) recipients. Like primary recip-
ients (Figures 4A and 4B), secondary recipients showed no dif-
ference in engraftment whether they received Egr1+/+ or Egr1/
BM (Figures 5A and 5B). However, upon transplantation to
Cell Stem Cell
EGR1 Regulates Hematopoietic Stem Cell HomeostasisFigure 4. Loss of Egr1 in BM Cells Does Not Impair Hematopoietic Engraftment Ability
(A) Noncompetitive BM transplantation. Lethally irradiated congenic CD45.1+ or F1 recipients received 500,000 CD45.2+ WBM cells from Egr1+/+ or Egr1/ mice.
The percent donor-derived cells among total blood leukocytes, total BM cells, and BM KLSF LT-HSCs was determined by flow cytometry and is plotted for each
individual recipient at 8 weeks posttransplant. Median values are indicated by the horizontal bars. Data are combined from two separate experiments and do not
differ significantly between recipients of Egr1+/+ or Egr1/ cells (analyzed by Wilcoxon test).
(B) Blood repopulation analysis of noncompetitively transplanted Egr1+/+ or Egr1/ WBM cells at 14 weeks after BM transplantation. Recipients of Egr1+/+ or
Egr1/ WBM cells exhibited no significant differences in the percent donor-derived peripheral blood leukocytes (shown as mean + SD, n = 5–6 recipients
per genotype).
(C–F) Competitive BM transplantation. WBM cells (25,000 or 100,000) from Egr1+/+ (A for 25,000 and> for 100,000) or Egr1/ (C for 25,000,B for 100,000)
were transplanted into lethally irradiated congenic recipients, along with 200,000 host-type competitor WBM cells. Data are plotted as mean (+SD) percent do-
nor-derived total blood leukocytes (C), Mac1+Gr1+ myeloid cells (D), CD3/4/8+ T cells (E), or B220+ B cells (F) in each transplantation setting, as determined by
flow cytometric analysis of recipient peripheral blood at 4, 6, 8, and 19 weeks posttransplant. Data are compiled from three independent experiments. Donor-
derived myeloid engraftment at 19 weeks was significantly higher in recipients of 25,000 Egr1/ cells as compared to recipients of 25,000 Egr1+/+ cells (*p% 0.05
by Wilcoxon test). Other differences were not statistically significant.Cell Stem Cell 2, 380–391, April 2008 ª2008 Elsevier Inc. 385tertiary recipients, Egr1/ BM exhibited significantly impaired
radioprotective ability, with only 2 of 5 recipients of Egr1/
BM, compared to 6 of 6 recipients of Egr1+/+ BM surviving >30
days (Figures 5A and 5C). Thus, although loss of EGR1 in
Egr1/ HSCs does not impair reconstitution capacity in primary
recipient mice, Egr1/ HSCs exhibit premature loss of function
during serial transplantation, which places substantial prolifera-
tive stress on the transplanted HSCs (Allsopp and Weissman,
2002). These data further support our finding that Egr1/
HSCs show a cell-intrinsic, enhanced proliferation of HSCs (Fig-
ures 2 and 3; see also the Supplemental Discussion).
Spontaneous, Constitutive Mobilization of HSCs
in Egr1/ Mice
The relative lack of expansion of BM LT-HSCs in Egr1/ mice
despite significant increases in the proliferative fraction of this
population and its normal rate of apoptosis implies that addi-
tional regulatory mechanisms act to limit HSC accumulation in
the BM of Egr1/ mice. In this regard, we were intrigued by
the substantial downregulation of Egr1 in premigratory BM
HSCs purified from D+2 Cy/G-treated mice. Because D+2
Cy/G HSCs represent an HSC population that is just about to
migrate from the BM and into the PB (Morrison et al., 1997),
these data suggested that EGR1 may play a role in retainingHSCs in the BM. Thus, we hypothesized that HSC frequency in
the BM could be maintained at near normal levels in Egr1/
mice by enhancing the release of ‘‘excess’’ HSCs from the BM.
To test the impact of loss of EGR1 on LT-HSC localization, we
analyzed LT-HSC frequency and number in the bloodstream of
Egr1+/+ and Egr1/ mice. Consistent with previous findings
(Fleming et al., 1993; Morrison et al., 1997; Wright et al.,
2001b), circulating LT-HSCs were extremely rare in the PB of
Egr1+/+ mice; however, in Egr1/ mice, both the frequency
and total number of circulating HSCs were dramatically in-
creased (up to 10-fold; **p < 0.01 by Wilcoxon test), as indicated
by flow cytometric detection of KLSF or KLSF34 LT-HSCs
(Figures 6A and 6B and data not shown). By comparison, HSC
frequencies and numbers were only slightly increased among
Egr1/ splenocytes (Figure S5).
We confirmed this striking increase of circulating LT-HSCs in
Egr1/ mice by transplantation of PB leukocytes from Egr1+/+
or Egr1/ mice into lethally irradiated recipients. Both Egr1+/+
and Egr1/ PB contributed to myeloid and lymphoid (T and B
cell) lineages in a subset of reconstituted mice (Figures 6C–6F).
However, 16 weeks after transplant, only 2 of 9 (22%) recipients
of Egr1+/+ cells maintained multilineage hematopoietic chime-
rism, in contrast to 8 of 9 (89%) Egr1/ recipients (p = 0.02 by
Fisher’s test). In addition, at 16 weeks posttransplant, Egr1/
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EGR1 Regulates Hematopoietic Stem Cell HomeostasisFigure 5. Egr1 Deficiency in Hematopoietic Cells Induces Rapid HSC Exhaustion in Serial BM Transplantation
(A) Analysis of radioprotection by donor Egr1+/+ or Egr1/ WBM cells in each round of serial BM transplantation. Donor Egr1+/+ or Egr1/ WBM cells were non-
competitively transplanted into lethally irradiated congenic wild-type recipients (0.53 106 donor cells/mouse; n = 13 per genotype) for the primary transplantation
(10 BMT). After 8 weeks, donor-derived WBM cells were isolated from the 10 transplant recipients by FACS, and secondarily transplanted into lethally irradiated
congenic recipients (13 106 donor cells/mouse; n = 13–14 per genotype) (20 BMT). Tertiary BM transplantation (30 BMT) was performed similarly 18 weeks after
20 BMT (n = 5–6 per genotype).
(B) Secondary blood repopulation analysis. The percentages of donor-derived total lymphocytes, myeloid cells, T cells, and B cells were analyzed by flow
cytometry 16 weeks after 20 BMT. Data show the average percent + SD.
(C) Kaplan-Meier survival curve of the 30 BMT shows the significant loss of radioprotective activity in recipients of Egr1/ donor BM cells relative to Egr1+/+
donors (p = 0.03 by log-rank test).PB cells exhibited superior average myeloid (p = 0.005) and lym-
phoid (T [p = 0.04] and B [p = 0.05]) engraftment, when compared
to Egr1+/+ PB cells (p values determined by Wilcoxon test). These
data are consistent with a markedly increased number of func-
tional LT-HSCs in the circulation of Egr1/ mice.
Finally, to test whether increases in circulating HSCs inEgr1/
mice result from loss of Egr1 in hematopoietic or nonhemato-
poietic cells, we analyzed chimeric mice previously transplanted
with eitherEgr1+/+ orEgr1/ BM cells (as in Figure 4A). Similar to
Egr1/mice, wild-type mice reconstituted withEgr1/BM cells
showed an increased frequency of HSCs among donor-derived
cells in the periphery (Figure S6). These data suggest that loss
of EGR1 activity specifically in the hematopoietic system pro-
motes spontaneous mobilization of functional HSCs from the
BM, although we cannot completely exclude the possibility that
EGR1 also plays additional non-cell-autonomous roles in regulat-
ing HSC mobilization. Significantly, the spontaneous mobilization
of HSCs in Egr1/ mice is not merely a result of their increased
proliferation, as p21/ mice, which also exhibit enhanced HSC
cycling (Cheng et al., 2000), do not exhibit increased frequencies
or numbers of LT-HSCs in their PB (Figure S7).
Egr1/ LT-HSCs Express Normal Levels of Adhesion
and Chemokine Receptors
The high level of LT-HSCs constitutively present in the circulation
of Egr1/ mice is one of the striking phenotypes of these ani-
mals, as transcriptional regulators that control HSC localization
have not previously been described. Previously reported media-
tors of HSC migration include cell surface expressed adhesion
proteins, chemokines and their receptors, and signaling mole-
cules of the small G protein family (reviewed in Winkler and Lev-
esque, 2006). To further investigate the mechanism(s) underlying
the spontaneous mobilization of HSCs in Egr1/ mice, we ana-
lyzed the expression of several genes previously implicated in
HSC migration and assayed the in vitro chemotactic capacity
and adhesion efficiency of Egr1/ LT-HSCs. However, we
saw no differences in Egr1+/+ versus Egr1/ HSCs in the386 Cell Stem Cell 2, 380–391, April 2008 ª2008 Elsevier Inc.expression or function of the integrin proteins a4 and b1 (Figures
S8A and S8B), of the SDF-1a receptor CXCR4 (Figure S9), or
in the expression of the small GTPases Rac1 and Rac2
(Figure S8C), all of which previously have been implicated in
HSC mobilization and/or BM homing (reviewed in Winkler and
Levesque, 2006). Taken together, these data exclude several
possible mechanisms (including altered integrin-mediated adhe-
sion and altered chemotactic activity) that might contribute to the
spontaneous mobilization of LT-HSCs in Egr1/ mice, and sug-
gest the existence of as yet unknown modulators of HSC migra-
tory activity. Egr1/ animals thus represent a novel model
for discovering pathways that control the in vivo localization
of HSCs.
DISCUSSION
To ensure appropriate homeostatic replacement of blood cells,
enable rapid regenerative responses to catastrophic blood loss
or disease, and limit proliferation-associated stem cell exhaus-
tion or transformation, HSC number and function must be tightly
regulated. Such regulation appears to be achieved through
a delicate balance of HSC developmental decisions, including
stem cell quiescence, self-renewal, differentiation, survival,
and migration. While some mediators of these processes are
known, the precise molecular circuitry controlling stem cell be-
havior has yet to be fully elucidated and the mechanisms by
which stem cells weigh these regulatory decisions remain mys-
terious. Here we present data demonstrating that at least one im-
portant determinant of HSC homeostasis is the transcription fac-
tor EGR1, which we show plays a dual role in negatively
regulating LT-HSC proliferation and mobilization (Figure 7). In
normal mouse BM, Egr1 is abundantly expressed by highly qui-
escent LT-HSCs, and is downregulated when these cells are in-
duced to divide and migrate in response to mobilizing stimuli.
Mice lacking EGR1 exhibit an increased fraction of proliferating
HSCs in the BM and increased numbers of circulating HSCs in
the periphery, indicating that the normal role of EGR1 is to
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EGR1 Regulates Hematopoietic Stem Cell HomeostasisFigure 6. Egr1/ Mice Exhibit Spontaneous Mobilization of HSCs into PB
(A) Representative FACS plots depicting higher frequencies of KLSF LT-HSCs in Egr1+/+ (top row) versus Egr1/ (bottom row) are shown. Plots on the left were
first gated on Lin PB leukocytes. Plots on the right show events in the c-kit+Sca-1+ gate (shown on the left). Numbers above each gate show the percentage of
events within the gate.
(B) Quantification of the overall frequency (percent of live PB leukocytes) and number of KLSF LT-HSCs in the PB of Egr1/ or Egr1+/+ mice. HSC frequencies
were determined by flow cytometry, with median (horizontal bar) shown on the boxplot. Differences between Egr1/ and Egr1+/+ mice are significant (**p% 0.01
by Wilcoxon test).
(C–F) Enhanced engraftment of recipient mice by Egr1/ PB cells. Lethally irradiated congenic recipients received 3 3 106 whole PB cells from Egr1+/+ (>,
dashed lines) or Egr1/ (C, solid lines) recipients, together with 3 3 105 host-type BM cells. Data are plotted for individual recipient mice as the percent do-
nor-derived total blood leukocytes (C), myeloid cells (D), T cells (E), or B cells (F), as determined by flow cytometric analysis of recipient PB at 6, 12, and 16 weeks
posttransplant. Recipients of Egr1/ PB cells showed significantly higher engraftment in all lineages at 16 weeks posttransplant, as compared to recipients of
Egr1+/+ PB cells (**p% 0.01, *p% 0.05 at week 16). Data are combined from two independent transplant experiments representing a total of nine animals per
genotype. Gray line indicates the background level of staining in each analysis.maintain HSC quiescence and limit HSC circulation. Thus, to our
knowledge this study identifies the first known transcriptional
regulator of HSC localization in vivo, and the first factor capable
of regulating both HSC cell division and mobilization responses.
The increased proliferation and spontaneous migration of
HSCs in Egr1/ mice appear to result from loss of EGR1 func-
tion specifically within the hematopoietic compartment, and
likely at least in part from loss of EGR1 within HSCs themselves.
Egr1/ LT-HSCs display an enhanced rate of proliferation whenmaintained clonally in culture and exhibit specific alterations in
their expression of known stem cell and cell-cycle regulatory
genes, including Bmi1 (Iwama et al., 2004; Lessard and Sauva-
geau, 2003; Park et al., 2003), cdk4 (Malumbres et al., 2004),
and p21 (Cheng et al., 2000). Finally, and most compellingly,
wild-type animals reconstituted with Egr1/ BM cells show
increased frequencies of donor-derived peripheral HSCs, as
compared to recipients of Egr1+/+ BM. Together, these data
argue strongly that cell-intrinsic changes resulting from theCell Stem Cell 2, 380–391, April 2008 ª2008 Elsevier Inc. 387
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EGR1 Regulates Hematopoietic Stem Cell HomeostasisFigure 7. EGR1 Plays a Dual Role in Limiting
LT-HSC Proliferation and Migration
Potential mechanisms of EGR1 function, sug-
gested by our studies, are indicated. Whether
crosstalk between HSC proliferation and migration
contributes to the coordinate regulation of LT-
HSCs by Egr1 remains to be determined.loss of EGR1 in Egr1/ LT-HSCs likely trigger altered HSC
behavior in Egr1/ mice.
The increased expression of Bmi1 in Egr1/ LT-HSCs sug-
gests that BMI1- and EGR1-regulated pathways may interact
directly to control HSC activity. BMI1 normally functions as
part of a chromatin-remodeling complex that promotes gene
silencing, and the importance of BMI1 in maintaining HSCs, as
well as neural stem cells, has been well documented (Iwama
et al., 2004; Lessard and Sauvageau, 2003; Molofsky et al.,
2005; Park et al., 2003). The increased Bmi1 mRNA levels in
Egr1/ LT-HSCs suggest that Bmi1 is a target of EGR1, or of
EGR1-induced signaling pathways, and that EGR1 normally
acts to repress Bmi1 expression. Likewise, the decreased
expression of p21cip1/Waf1 and elevated cdk4 expression in
Egr1/ LT-HSCs suggest that EGR1 normally targets both reg-
ulatory and core components of the cell-cycle machinery to
block HSC overproliferation. Interestingly, both p21 and CDK4
have been implicated specifically in maintaining appropriate
HSC function (Cheng et al., 2000; Malumbres et al., 2004).
Thus, EGR1 appears to play an important role in balancing the
expression of stem cell-relevant cell-cycle regulators to maintain
quiescence in the BM niche.
One of the most striking features of the HSC phenotype of
Egr1/ mice is the enhanced constitutive mobilization of these
cells into the bloodstream. PB from Egr1/ mice contained sig-
nificantly higher numbers of functional LT-HSCs, as assayed by
both flow cytometry and competitive transplantation. However,
we found no detectable differences in the cell surface protein
or mRNA levels of several molecules known to mediate HSC
movement, including VLA-4, CXCR4, RAC1, and RAC2, or in
the in vitro adhesion or migration responses of these cells to
the integrin ligand fibronectin, the stem cell chemoattractant
SDF-1a, or the cytokine SLF. These data exclude several known
adhesion/chemokine receptors as potential mediators of spon-
taneous HSC mobilization in Egr1/ mice and suggest that as
yet undiscovered signaling pathways modulate HSC migratory
activity in this model. Egr1/ mice represent one of only a few
mouse models that exhibit spontaneous HSC migration without
pathological abnormalities, and thus provide a powerful new tool
for future studies to identify novel molecular pathways involved
in HSC mobilization.
The demonstration that mice deficient in EGR1 show simulta-
neous perturbations of HSC proliferation and localization indi-
cates the ability of a single transcription factor, EGR1, to coordi-
nate control of both HSC cell-cycle progression and migration
(Figure 7). As we have just begun to elucidate the molecular tar-
gets of this transcription factor, it remains unclear to what degree388 Cell Stem Cell 2, 380–391, April 2008 ª2008 Elsevier Inc.the targets of EGR1 that are important for regulating proliferation
are the same as those that regulate HSC localization, or whether
crosstalk between these two stem cell regulatory processes
contributes to EGR1 function. However, it is clear that induction
of HSC proliferation in the BM niche does not lead obligatorily to
HSC mobilization, as HSC localization is unperturbed in p21/
mice, despite significantly increased HSC cycling in these ani-
mals (Cheng et al., 2000; I.M.M., unpublished data). Thus, HSC
proliferation per se is insufficient to induce HSC mobilization,
emphasizing the unique activity of EGR1 in coregulating these
two processes. Finally, given the relatively normal frequency of
HSCs in Egr1/ BM, we speculate that this molecular coordina-
tion may provide a novel mechanism for maintaining constant
numbers of HSCs in the BM while allowing HSC proliferation to
generate differentiated daughters.
From a therapeutic standpoint, the dual effects of reduced
EGR1 activity in increasing HSC proliferation and promoting
HSC peripheralization suggest a unique opportunity to target
this pathway to manipulate stem cell activity in the context of
clinical hematopoietic cell mobilization and transplantation.
Despite the increased use of mobilized peripheral blood cells
as a source of engrafting HSCs for transplantation, patients
who undergo repeated mobilization treatments, and even
healthy donors, can be refractory to conventional mobilization
treatments (Copelan, 2006). In addition, susceptibility to oppor-
tunistic infections still represents a major complication associ-
ated with hematopoietic transplantation procedures, and is
particularly concerning during the period of hematodeficiency
that immediately follows transplantation. Thus, mechanisms
that speed recovery of normal levels of circulating blood cells
would benefit transplant patients by reducing this period of
vulnerability. In this regard, our data suggest that transient
downregulation of Egr1 in HSCs might serve as an additional
or alternative method to induce or accentuate HSC mobilization,
or to promote HSC expansion in vivo at early time points after
transplantation. These manipulations could potentially acceler-
ate hematopoietic engraftment and/or enable successful trans-
plantation in situations in which numbers of reconstituting
HSCs are limiting.
In conclusion, the studies reported here define a novel role for
the transcription factor EGR1 in maintaining quiescence and de-
termining the in vivo localization of HSCs. The future study of
EGR1 target genes and EGR1-regulated signaling pathways
will help to better define the molecular mechanisms that control
normal HSC function, stimulate HSC expansion and migration,
and potentially limit HSC overproliferation leading to leukemic
transformation.
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Mice
Egr1tm2Jm1 transgenic mice (Lee et al., 1995a, 1996a) were purchased from
Taconic, and p21tm1Tyj transgenic (Cheng et al., 2000) and CD45.1+ B6.SJL
mice were purchased from the Jackson laboratory. All mice used in this study
were at least 8 weeks of age. All animal experiments were approved by Insti-
tutional Animal Care and Use Committees (IACUC).
Flow Cytometric Analysis of HSCs
BM cells from femurs and tibiae were prepared and stained, as in Wright et al.
(2001b). PB was collected by transcardiac perfusion with 20 ml 10 mM EDTA/
13PBS and prepared for staining, as in Wright et al. (2001b). To identify HSCs,
BM or PB cell pellets were stained with antibodies identifying Lineage markers
(CD3 [145-2C11], CD4 [GK1.5], CD5 [53-7.3], CD8 [53-6.7], B220 [RA3-6B2],
Mac1 [M1/70], Gr1 [RB6-8C5], and Ter119), c-kit, Sca-1, Flk2, and/or CD34.
To distinguish donor from host cells in transplanted mice, cells were addition-
ally stained with anti-CD45.2 or CD45.1, and to analyze expression of cell
adhesion molecule, cells were additionally stained with anti-b1-integrin, anti-
a4 integrin, or anti-CXCR4. Details of cell staining and flow cytometry proto-
cols are available in the Supplemental Experimental Procedures.
Cell-Cycle Analysis of BM LT-HSCs
Hoechst staining was performed essentially as described in Passegue et al.
(2005). For in vivo BrdU incorporation studies, mice received 1 mg/ml of
BrdU (Sigma) by i.p. injection and were sacrificed 1 hr later. RBC-lysed BM
cells were surface stained with KLS34-LT-HSC markers and then fixed in
1% paraformaldehyde containing 0.01% Tween-20 in PBS for 24 hr at 4C
in the dark. After washing, cells were incubated with 50 U of DNase (Roche)
for 1 hr at room temperature. After another wash step, BM cells were incubated
in PBS containing 0.5% Tween-20 and FITC-conjugated anti-BrdU or isotype
control antibody (BD Biosciences) for 30 min at room temperature. BrdU incor-
poration was analyzed by flow cytometry, with BrdU+ cells identified based on
staining with isotype control antibody. In separate experiments to assess
apoptosis, cells were costained with Annexin V (BD Pharmingen) in conjunc-
tion with HSC markers.
To follow the growth of single LT-HSCs over time, double-sorted HSCs were
directly deposited into individual wells of round-bottom 96-well plates and
maintained in serum-free StemSpan medium (StemCell Technologies) with
300 ng/ml SCF, 20 ng/ml IL-11, 1 ng/ml Flt-3 ligand, 50 ng/ml thrombopoietin,
and 104 M b-mercaptoethanol (all cytokines from R&D Systems) (Ema et al.,
2000; Uchida et al., 2003). Cells were counted daily by light microscopy.
5-fluorouracil (5-FU) was administered by i.p. injection (5 mg/mouse). One
day after 5-FU administration, BM HSCs were identified by flow cytometry
analysis using the marker profile KLSF34.
Isolation of HSCs for Quantitative RT-PCR
BM cells were collected after crushing femurs, tibiae, and pelvic bones with
a mortar and pestle, and were depleted of lineage marker-positive cells by
magnetic selection, as described in the Supplemental Experimental Proce-
dures. Alternatively, BM was enriched for cells expressing c-Kit using Miltenyi
CD117 microbeads and an AutoMACS magnetic selection device (Miltenyi
Biotec). Lineage-depleted or c-Kit-enriched WBM cells were further stained
for HSC markers as above. HSCs were double sorted into cell lysis buffer
(QIAGEN RNeasy), and mRNA was extracted according to the manufacturer’s
protocol. cDNA was generated from mRNA using TaqMan reverse transcrip-
tion reagents (Applied Biosystems). cDNA from 50–200 HSC equivalents
was used in a single reaction to amplify specific transcripts. All PCR reactions
were performed in duplicate using SYBR green PCR master mix (Applied Bio-
systems), and data were acquired on an ABI PRISM 7000. Primer sequences
are provided in Table S1.
BM and PB Transplantation
Noncompetitive and competitive BM transplantation, competitive BM HSC
transplantation, and PB transplantation were performed by retroorbital injec-
tion of donor CD45.2+ BM, HSC, or PB cells from Egr1+/+ or Egr1/ into
lethally irradiated congenic wild-type recipients. In all cases, total body irradi-
ation was delivered in a single dose of 950 rad using a J.L. Shepard 6810sealed-source 137Cs irradiator. PB of reconstituted mice was analyzed by
flow cytometry to determine blood repopulation efficiency, as in Passegue
et al. (2005). We considered mice to be long-term, multilineage reconstituted
when the percentages of both donor-derived lymphoid (B and T) and myeloid
cells were at least 1.5 standard deviations above the average background
staining for the donor CD45.2 marker (determined by parallel staining of un-
transplanted CD45.1+ or F1 control mice) at week 16 (PB transplantation) or
19 (BM transplantation) after transplantation.
HSC Chemotaxis and Assays
Chemotaxis assays were performed and analyzed essentially as in Christen-
sen et al. (2004) and Wright et al. (2002). Adhesion assays for fibronectin bind-
ing were performed using a modification of the technique described by Yang
et al. (2001). Additional experimental details are available in the Supplemental
Experimental Procedures.
Statistical Analysis
Unless otherwise noted, unpaired Student’s t tests were used to determine
statistical significance (p% 0.05). Comparisons of HSC frequency, HSC cycle
distribution, and transplant recipients of Egr1+/+ and Egr1/ mice were ana-
lyzed by Wilcoxon rank-sum test. Fisher’s exact tests were used to analyze
differences between the numbers of multilineage reconstituted mice among
recipients of Egr1+/+ or Egr1/ BM or HSCs. Kaplan and Meier method was
used to estimate the survival curves, and the log-rank test was used for
comparison. All statistical analyses were performed using SAS software (SAS
Institute, NC).
SUPPLEMENTAL DATA
Supplemental Data include nine figures, one table, Supplemental Discussion,
Supplemental Experimental Procedures, and Supplemental References and
can be found with this article online at http://www.cellstemcell.com/cgi/
content/full/2/4/380/DC1/.
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